C4 Therapeutics, Inc. Earnings Per Share (Diluted)
C4 Therapeutics, Inc. (CCCC) reported Earnings Per Share (Diluted) of -$0.18 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-11
- C4 Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.18.
- C4 Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.20.
- C4 Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.17.
- C4 Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.44.
- C4 Therapeutics, Inc. earnings per share, diluted for fiscal 2025 was -$1.27.
- C4 Therapeutics, Inc. earnings per share, diluted for fiscal 2024 was -$1.52.
- C4 Therapeutics, Inc. earnings per share, diluted for fiscal 2023 was -$2.67.
- C4 Therapeutics, Inc. earnings per share, diluted for fiscal 2022 was -$2.62.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.18 10-Q · filed 2026-08-11 | -$0.38 10-Q · filed 2026-08-11 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.20 10-Q · filed 2026-05-12 | -$0.38 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.27 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.44 10-Q · filed 2025-11-06 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.18 10-Q · filed 2025-11-06 | -$1.67 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.37 10-Q · filed 2026-08-11 | -$0.74 10-Q · filed 2026-08-11 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.58 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$0.37 10-Q · filed 2026-05-12 | -$0.86 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.48 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2024-12-31 | -$0.49 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.10 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.52 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.35 10-Q · filed 2025-11-06 | -$0.61 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.03 10-Q · filed 2025-11-06 | -$1.63 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2024-06-30 | -$0.26 10-Q · filed 2025-08-07 | -$0.67 10-Q · filed 2025-08-07 | -$1.29 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.82 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2024-03-31 | -$0.41 10-Q · filed 2025-05-07 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.60 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$2.31 derived: net income ÷ weighted average shares · filed 2026-04-29 |
| 2023-12-31 | -$0.68 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.96 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$2.67 10-K · filed 2025-02-27 |
| 2023-09-30 | -$0.55 10-Q · filed 2024-10-31 | -$1.28 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$1.99 10-Q · filed 2024-10-31 | -$2.75 derived: net income ÷ weighted average shares · filed 2024-10-31 |
| 2023-06-30 | -$0.73 10-Q · filed 2024-08-01 | -$1.44 10-Q · filed 2024-08-01 | -$2.20 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$2.85 derived: net income ÷ weighted average shares · filed 2024-10-31 |
| 2023-03-31 | -$0.71 10-Q · filed 2024-05-08 | -$1.47 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$2.12 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$2.68 derived: net income ÷ weighted average shares · filed 2024-10-31 |
| 2022-12-31 | -$0.76 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$1.41 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$1.97 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$2.62 10-K · filed 2024-02-22 |
| 2022-09-30 | -$0.65 10-Q · filed 2023-11-01 | -$1.21 derived: net income ÷ weighted average shares · filed 2023-11-01 | -$1.86 10-Q · filed 2023-11-01 | -$2.19 derived: net income ÷ weighted average shares · filed 2023-11-01 |
| 2022-06-30 | -$0.56 10-Q · filed 2023-08-08 | -$1.21 10-Q · filed 2023-08-08 | -$1.53 derived: net income ÷ weighted average shares · filed 2023-11-01 | -$2.04 derived: net income ÷ weighted average shares · filed 2023-11-01 |
| 2022-03-31 | -$0.65 10-Q · filed 2023-05-04 | -$0.97 derived: net income ÷ weighted average shares · filed 2023-11-01 | -$1.48 derived: net income ÷ weighted average shares · filed 2023-11-01 | -$1.99 derived: net income ÷ weighted average shares · filed 2023-11-01 |
| 2021-12-31 | -$0.32 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$0.83 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$1.34 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$1.82 10-K · filed 2023-02-23 |
| 2021-09-30 | -$0.51 10-Q · filed 2022-11-03 | -$1.02 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.51 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$0.51 10-Q · filed 2022-08-04 | -$1.00 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |